{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:30:47Z","timestamp":1785403847316,"version":"3.56.0"},"reference-count":111,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Medicine and Pharmacy of Craiova, Romania"},{"id":[{"id":"https:\/\/ror.org\/031d5vw30","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease characterized by substantial clinical and immunological heterogeneity. Once considered primarily a disorder of epidermal barrier dysfunction, AD is now recognized as a complex systemic inflammatory condition involving dysregulated immune responses, epithelial-derived signaling, neuroimmune interactions, and diverse molecular endotypes. Advances in molecular immunology have substantially improved understanding of the cytokine networks underlying disease pathogenesis and have accelerated the transition toward precision medicine approaches in AD. This narrative review summarizes current evidence regarding the immunopathogenesis of AD, focusing on the interplay between classical and emerging cytokine pathways, biomarker development, and recent therapeutic innovations. While interleukin (IL)-4 and IL-13 remain central drivers of type 2 inflammation and barrier impairment, additional mediators including IL-31, IL-33, IL-22, thymic stromal lymphopoietin (TSLP), and OX40\/OX40L signaling, and the emerging Th9\/IL-9 axis contribute to chronic inflammation, neuroimmune activation, epidermal remodeling, pruritus, and disease heterogeneity. Comparative evaluation of these pathways supports the identification of distinct immunological endotypes relevant to disease stratification and targeted therapy. The review further discusses current and emerging biomarkers associated with disease severity, therapeutic responsiveness, and inflammatory profiling, including cytokine signatures, serum biomarkers, and transcriptomic approaches. Recent advances in biologic therapies, Janus kinase (JAK) inhibitors, and novel cytokine-targeted interventions are discussed within the context of a precision medicine framework integrating immunological profiling, molecular endotyping, and mechanism-based therapeutic innovation. Continued advances in biomarker discovery, multi-omics technologies, and predictive therapeutic algorithms are expected to further refine disease stratification and support increasingly individualized management strategies for patients with AD.<\/jats:p>","DOI":"10.3390\/ijms27146129","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:16:22Z","timestamp":1783592182000},"page":"6129","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Atopic Dermatitis Beyond the Skin Barrier: Precision Medicine Approaches to Immunological Profiling and Therapeutic Innovation"],"prefix":"10.3390","volume":"27","author":[{"given":"Virgilios","family":"Galatis","sequence":"first","affiliation":[{"name":"Doctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabela","family":"Silo\u0219i","sequence":"additional","affiliation":[{"name":"Department of Immunology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3146-8769","authenticated-orcid":false,"given":"Mohamed-Zakaria","family":"Assani","sequence":"additional","affiliation":[{"name":"Doctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"},{"name":"Department of Immunology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4817-1365","authenticated-orcid":false,"given":"Lidia","family":"Boldeanu","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George G.","family":"Mitroi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2481-6138","authenticated-orcid":false,"given":"Mihail Virgil","family":"Boldeanu","sequence":"additional","affiliation":[{"name":"Department of Immunology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Makowska, K., Nowaczyk, J., Blicharz, L., Wa\u015bkiel-Burnat, A., Czuwara, J., Olszewska, M., and Rudnicka, L. (2023). Immunopathogenesis of Atopic Dermatitis: Focus on Interleukins as Disease Drivers and Therapeutic Targets for Novel Treatments. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24010781"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","article-title":"Atopic dermatitis","volume":"4","author":"Weidinger","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.jaci.2021.01.013","article-title":"Biomarkers in atopic dermatitis-a review on behalf of the International Eczema Council","volume":"147","author":"Thyssen","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Prados-Carmona, A., Husein-ElAhmed, H., Navarro-Trivi\u00f1o, F.J., and Ruiz-Villaverde, R. (2025). From Pathways to Patients in Atopic Dermatitis: Advanced Systemic Therapies. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262311487"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Chiricozzi, A., Levi, A., Palladino, C., and Girolomoni, G. (2025). Enabling precision medicine with biomarkers of response to treatment in atopic dermatitis: Where are we now? A narrative review. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1574697"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"\u0141acwik, J., Kraik, K., Laska, J., Tota, M., S\u0119dek, \u0141., and Gomu\u0142ka, K. (2025). IL-31\/33 Axis in Atopic Dermatitis. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262010162"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Bili\u0144ski, K., Rakoczy, K., Karwowska, A., Cichy, O., Wojno, A., Wojno, A., Kulbacka, J., and Ponikowska, M. (2025). Anti-Inflammatory Therapies for Atopic Dermatitis: A New Era in Targeted Treatment. J. Clin. Med., 14.","DOI":"10.3390\/jcm14145053"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Hansen-Sackey, E.B., and Hartono, S. (2025). Atopic Dermatitis: Pathophysiology and Emerging Treatments. Allergies, 5.","DOI":"10.3390\/allergies5040040"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Smolinska, S., Antol\u00edn-Am\u00e9rigo, D., Popescu, F.-D., and Jutel, M. (2023). Thymic Stromal Lymphopoietin (TSLP), Its Isoforms and the Interplay with the Epithelium in Allergy and Asthma. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241612725"},{"key":"ref_10","first-page":"97","article-title":"Pathogenesis of Atopic Dermatitis: Current Paradigm","volume":"16","author":"Furue","year":"2019","journal-title":"Iran. J. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.jid.2018.12.018","article-title":"Atopic Dermatitis Is an IL-13-Dominant Disease with Greater Molecular Heterogeneity Compared to Psoriasis","volume":"139","author":"Tsoi","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s43556-025-00313-3","article-title":"Atopic dermatitis: Diagnosis, molecular pathogenesis, and therapeutics","volume":"6","author":"Bai","year":"2025","journal-title":"Mol. Biomed."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00403-024-03546-4","article-title":"Factors associated with comorbidity development in atopic dermatitis: A cross-section study","volume":"317","author":"Jiang","year":"2024","journal-title":"Arch. Dermatol. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0140-6736(24)01203-0","article-title":"ARCADIA 1 and ARCADIA 2 Study Investigators. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): Results from two replicate, double-blind, randomised controlled phase 3 trials","volume":"404","author":"Silverberg","year":"2024","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1038\/s41467-026-69587-7","article-title":"Multi-modal skin atlas identifies a multicellular immune-stromal community associated with disrupted cornification and specific T cell expansion in atopic dermatitis","volume":"17","author":"Fiskin","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/jdv.70080","article-title":"Safety and efficacy of nemolizumab for atopic dermatitis up to 2\u2009years in open-label extension study","volume":"40","author":"Augustin","year":"2026","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Chiricozzi, A., Maurelli, M., Calabrese, L., Peris, K., and Girolomoni, G. (2023). Overview of Atopic Dermatitis in Different Ethnic Groups. J. Clin. Med., 12.","DOI":"10.20944\/preprints202302.0458.v1"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/exd.13514","article-title":"Atopic dermatitis in diverse racial and ethnic groups-Variations in epidemiology, genetics, clinical presentation and treatment","volume":"27","author":"Kaufman","year":"2018","journal-title":"Exp. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"eaat5943","DOI":"10.1126\/sciimmunol.aat5943","article-title":"Human \u201cTH9\u201d cells are a subpopulation of PPAR-\u03b3+ TH2 cells","volume":"4","author":"Steck","year":"2019","journal-title":"Sci. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1007\/s13555-024-01308-8","article-title":"A Narrative Review of the OX40-OX40L Pathway as a Potential Therapeutic Target in Atopic Dermatitis: Focus on Rocatinlimab and Amlitelimab","volume":"14","author":"Abdelhalim","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Sadrolashrafi, K., Guo, L., Kikuchi, R., Hao, A., Yamamoto, R.K., Tolson, H.C., Bilimoria, S.N., Yee, D.K., and Armstrong, A.W. (2024). An OX-Tra\u2019Ordinary Tale: The Role of OX40 and OX40L in Atopic Dermatitis. Cells, 13.","DOI":"10.3390\/cells13070587"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/bjd\/ljae230","article-title":"The role of OX40 ligand\/OX40 axis signaling in atopic dermatitis","volume":"191","author":"Croft","year":"2024","journal-title":"Br. J. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s41687-025-00871-8","article-title":"Patient-reported outcome assessment of adults and adolescents with atopic dermatitis: A cross-sectional qualitative interview study","volume":"9","author":"Ghafoori","year":"2025","journal-title":"J. Patient Rep. Outcomes"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jaip.2024.03.050","article-title":"Patient-Reported Outcome Measures in Atopic Dermatitis and Chronic Urticaria Are Underused in Clinical Practice","volume":"12","author":"Bousquet","year":"2024","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/bjd\/ljae232","article-title":"Mapping SCORing of Atopic Dermatitis (SCORAD) and objective SCORAD to the Eczema Area and Severity Index to facilitate large-scale meta-analyses of molecular data","volume":"191","author":"Dai","year":"2024","journal-title":"Br. J. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/j.jaci.2017.04.052","article-title":"Relationship between EASI and SCORAD severity assessments for atopic dermatitis","volume":"140","author":"Chopra","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.anai.2025.06.020","article-title":"New treatments in atopic dermatitis update","volume":"135","author":"Gallagher","year":"2025","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"745.e1","DOI":"10.1016\/j.jaad.2025.05.1386","article-title":"Focused update: Guidelines of care for the management of atopic dermatitis in adults","volume":"93","author":"Davis","year":"2025","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.jaci.2023.01.019","article-title":"Biomarkers in atopic dermatitis","volume":"151","author":"Bakker","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Kataoka, Y. (2025). Thymus and activation-regulated chemokine (CCL17) as a clinical biomarker in atopic dermatitis: Significance and limitations in the new treatment era. Front. Allergy, 5.","DOI":"10.3389\/falgy.2024.1473902"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/cea.14637","article-title":"Increased Levels of Inflammatory Proteins, Including TARC\/CCL17, in Skin of AD Patients During JAK Inhibitor Treatment","volume":"55","author":"Boesjes","year":"2025","journal-title":"Clin. Exp. Allergy"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3892\/etm.2025.12888","article-title":"Effect of dupilumab for the therapy of atopic dermatitis and the effect on serum TARC, HBD2 and SEA-IgE levels and peripheral blood T helper cell subtypes","volume":"30","author":"Tian","year":"2025","journal-title":"Exp. Ther. Med."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Sonnenberg-Riethmacher, E., Miehe, M., and Riethmacher, D. (2021). Periostin in Allergy and Inflammation. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.722170"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"100991","DOI":"10.1016\/j.waojou.2024.100991","article-title":"Evaluating serum periostin and YKL-40 as biomarkers for airway remodeling and hyperresponsiveness in pediatric asthma","volume":"17","author":"Kim","year":"2024","journal-title":"World Allergy Organ. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.alit.2023.06.001","article-title":"Pretreatment circulating MAIT cells, neutrophils, and periostin predicted the real-world response after 1-year mepolizumab treatment in asthmatics","volume":"73","author":"Sasano","year":"2024","journal-title":"Allergol. Int."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Ono, J., Takai, M., Kamei, A., Azuma, Y., and Izuhara, K. (2021). Pathological Roles and Clinical Usefulness of Periostin in Type 2 Inflammation and Pulmonary Fibrosis. Biomolecules, 11.","DOI":"10.3390\/biom11081084"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jaci.2020.05.048","article-title":"Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis","volume":"147","author":"He","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Grieco, T., Paolino, G., Moliterni, E., Chello, C., Sernicola, A., Egan, C.G., Morelli, M., Nannipieri, F., Battaglia, S., and Accoto, M. (2025). Transcriptomic Profiling of Lesional and Perilesional Skin in Atopic Dermatitis Suggests Barrier Dysfunction, Inflammatory Activation, and Alterations to Vitamin D Metabolism. Int. J. Mol. Sci., 26.","DOI":"10.20944\/preprints202505.0865.v1"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00438-020-01754-x","article-title":"Profiling transcriptomic changes and signaling pathways in atopic dermatitis by integrative analyses on multiple databases","volume":"296","author":"Xu","year":"2021","journal-title":"Mol. Genet. Genom."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1038\/s41467-025-59340-x","article-title":"An unbiased tissue transcriptome analysis identifies potential markers for skin phenotypes and therapeutic responses in atopic dermatitis","volume":"16","author":"Kawasaki","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"SOLO 1 and SOLO 2 Investigators. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Pelaia, C., Pelaia, G., Crimi, C., Maglio, A., Armentaro, G., Calabrese, C., Sciacqua, A., Gallelli, L., and Vatrella, A. (2022). Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13. Vaccines, 10.","DOI":"10.3390\/vaccines10060974"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation","volume":"75","author":"Allinne","year":"2020","journal-title":"Allergy"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): A 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1001\/jamadermatol.2024.1536","article-title":"Dupilumab in Adults with Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension Study","volume":"160","author":"Beck","year":"2024","journal-title":"JAMA Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1093\/ced\/llae208","article-title":"Short-, mid- and long-term efficacy of dupilumab in moderate-to-severe atopic dermatitis: A real-world multicentre Italian study of 2576 patients","volume":"49","author":"Ferrucci","year":"2024","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s13555-025-01563-3","article-title":"Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis","volume":"16","author":"Augustin","year":"2026","journal-title":"Dermatol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/ajd.14358","article-title":"Safety and efficacy of biologic drugs in children or adolescents with atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials","volume":"65","author":"Zamora","year":"2024","journal-title":"Australas. J. Dermatol."},{"key":"ref_50","first-page":"2021-1-7","article-title":"Selective IL-13 inhibitors for the treatment of atopic dermatitis","volume":"10","author":"Freitas","year":"2021","journal-title":"Drugs Context."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Lytvyn, Y., and Gooderham, M. (2023). Targeting Interleukin 13 for the Treatment of Atopic Dermatitis. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15020568"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"van derGang, L.F., Zuithoff, N.P.A., Haeck, I.M., Harbers, V.E.M., Stadhouders-Keet, S., Politiek, K., Oosting, A.J., van Lynden-van Nes, A.M.T., Lam, H.Y., and van Tuyll van Serooskerken, A.M. (2026). Dupilumab versus tralokinumab in atopic dermatitis: A propensity score adjusted comparison from BioDay. J. Eur. Acad. Dermatol. Venereol., advance online publication.","DOI":"10.1111\/jdv.70442"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/1346-8138.70187","article-title":"Seventy-Two-Week Real-World Outcomes of Tralokinumab Treatment for Moderate-To-Severe Atopic Dermatitis: Analyses Stratified by Baseline Rash and Itch Severity","volume":"53","author":"Yoneyama","year":"2026","journal-title":"J. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s13555-026-01656-7","article-title":"Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND","volume":"16","author":"Blauvelt","year":"2026","journal-title":"Dermatol. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/1346-8138.70138","article-title":"Long-Term, Site-Specific Effectiveness of Tralokinumab in Atopic Dermatitis: A 72-Week Real-World Study","volume":"53","author":"Shiba","year":"2026","journal-title":"J. Dermatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/jdv.70165","article-title":"Efficacy of up to 4\u2009years of tralokinumab in adults with moderate-to-severe atopic dermatitis","volume":"40","author":"Gooderham","year":"2026","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1007\/s13555-026-01726-w","article-title":"Real-World Effectiveness and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Italian Study Focusing on Head and Neck Involvement","volume":"16","author":"Gargiulo","year":"2026","journal-title":"Dermatol. Ther."},{"key":"ref_58","first-page":"e105706","article-title":"Biologic Monotherapies for Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Bayesian Network Meta-Analysis of Established and Investigational Agents","volume":"18","author":"Babul","year":"2026","journal-title":"Cureus"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Lopez-Mallama, O.M., Sandoval-Ato, R., Vega, P.R., Keita, H., Diaz-Gonzales, G., Rivera-Lozada, O., and Barboza, J.J. (2026). Efficacy and Safety of Lebrikizumab in Adults with Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-Analysis. J. Clin. Med., 15.","DOI":"10.3390\/jcm15051737"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s13555-025-01644-3","article-title":"Lebrikizumab Improves Clinical Manifestations, Symptoms, and Quality of Life in Patients with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab: Results from the ADapt Study","volume":"16","author":"Silverberg","year":"2026","journal-title":"Dermatol. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2","DOI":"10.25251\/tvshr813","article-title":"The role of interleukin-13 in the management of atopic dermatitis: An expert consensus panel","volume":"31","author":"DeBusk","year":"2025","journal-title":"Dermatol. Online J."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1007\/s13555-025-01550-8","article-title":"Effectiveness, Safety, and Health-Related Quality of Life in Moderate-to-Severe Atopic Dermatitis Treated with Lebrikizumab: A 16-Week Nationwide Retrospective Cohort Study","volume":"15","author":"Avallone","year":"2025","journal-title":"Dermatol. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e102155","DOI":"10.1136\/bmjopen-2025-102155","article-title":"European, multicentre, prospective observational phase IV clinical study to assess the impact of lebrikizumab on health-related well-being and control of skin manifestations in patients with moderate-to-severe atopic dermatitis (ADTrust): Study protocol","volume":"15","author":"Augustin","year":"2025","journal-title":"BMJ Open"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1007\/s13555-025-01452-9","article-title":"Two-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)","volume":"15","author":"Weidinger","year":"2025","journal-title":"Dermatol. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"583223","DOI":"10.2147\/CCID.S583223","article-title":"Real-World Experience with Upadacitinib in Patients with Atopic Dermatitis and Hidradenitis Suppurativa: A Dual-Center Case Series","volume":"19","author":"Martora","year":"2026","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Russo, F., Schettini, N., Scaglione, G.L., Gori, N., Manzo Margiotta, F., Del Duca, E., Bianchelli, T., Calabrese, L., Antonelli, E., and Giuliani, F. (2026). Beneficial effects of upadacitinib on a subgroup of patients with atopic dermatitis and hidradenitis suppurativa: A multicenter, real-world retrospective study. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1770969"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1007\/s13555-026-01690-5","article-title":"Upadacitinib for Atopic Dermatitis Involving Special and Sensitive Areas: Real-World Multicenter Outcomes in Hand, Head\/Neck, and Genital Involvement","volume":"16","author":"Martorell","year":"2026","journal-title":"Dermatol. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s40257-025-01003-0","article-title":"Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis After Inadequate Response to Dupilumab: Efficacy and Safety Results from Period 2 of Phase 3b\/4 Study (LEVEL UP)","volume":"27","author":"Bunick","year":"2026","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"68","DOI":"10.25259\/IJDVL_133_2025","article-title":"Upadacitinib in dermatology: A systematic review of mechanism, current applications, efficacy, safety, and emerging evidence","volume":"92","author":"Dogra","year":"2026","journal-title":"Indian. J. Dermatol. Venereol. Leprol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s13555-026-01679-0","article-title":"Real-World Effectiveness and Safety of Abrocitinib in Patients with Atopic Dermatitis: A 16-Week Single-Center Retrospective Cohort Study Compared with Upadacitinib and Baricitinib","volume":"16","author":"Gwag","year":"2026","journal-title":"Dermatol. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Yosipovitch, G., Gooderham, M.J., Elmariah, S.B., Bonfanti, G., Edwards, R.A., Gregoriou, S., Biswas, P., Myers, D.E., Alderfer, J., and G\u00fcler, E. (2026). Itch Relief and Quality-of-Life Improvement with Abrocitinib and Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE COMPARE and JADE DARE. Am. J. Clin. Dermatol., advance online publication.","DOI":"10.1007\/s40257-026-01030-5"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Gooderham, M.J., Silverberg, J.I., De Bruin-Weller, M., Kircik, L., Tha\u00e7i, D., Zhao, Z., Valenzuela, F., Nomura, T., Selfridge, A., and Fan, D. (2026). Long-term efficacy of abrocitinib in patients with moderate-to-severe atopic dermatitis to 2\u2009years. J. Eur. Acad. Dermatobil. Venereol., advance online publication.","DOI":"10.1111\/jdv.70439"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1007\/s13555-026-01695-0","article-title":"Long-Term Effectiveness and Safety of Abrocitinib in Patients with Atopic Dermatitis: A Real-World, Retrospective Study","volume":"16","author":"Tsiogka","year":"2026","journal-title":"Dermatol. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s13555-026-01655-8","article-title":"Real-World Characteristics, Treatment Patterns, and Outcomes in Adult Patients Receiving Abrocitinib for Atopic Dermatitis in China: Interim Analysis from the AHEAD Registry","volume":"16","author":"Zhang","year":"2026","journal-title":"Dermatol. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2585244","DOI":"10.1080\/09546634.2025.2585244","article-title":"Maintained improvement of outcomes related to skin clearance, itch, sleep and quality of life with baricitinib in adults with moderate-to-severe Atopic Dermatitis who were treated for up to 200 weeks in a randomized trial","volume":"36","author":"Wollenberg","year":"2025","journal-title":"J. Dermatol. Treat."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2578249","DOI":"10.1080\/09546634.2025.2578249","article-title":"Baricitinib for adult atopic dermatitis: Real-world effectiveness, safety, and response predictors","volume":"36","author":"Gori","year":"2025","journal-title":"J. Dermatol. Treat."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s13555-024-01330-w","article-title":"Baricitinib Provides Significant Improvements in Quality of Life and Functioning in Adults with Moderate-to-Severe Atopic Dermatitis with Baseline Body Surface Area\u2009 \u2264 \u200940% and Severe Itch","volume":"15","author":"Augustin","year":"2025","journal-title":"Dermatol. Ther."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Almoghayer, I.H.I., Soomro, A.M., Dev, S., Turesh, M., Kumar, A., Kumar, R., Meghjiani, A., Lamiya Mir, S., Hassaan, M., and Qureshi, R. (2024). Baricitinib as monotherapy and with topical corticosteroids in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis of dose-response. Front. Allergy, 5.","DOI":"10.3389\/falgy.2024.1486271"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/j.jaip.2024.04.008","article-title":"Comprehensive real-world comparisons between baricitinib and dupilumab treatments for moderate to severe atopic dermatitis","volume":"12","author":"Cho","year":"2024","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00441-023-03816-z","article-title":"The benefits and pitfalls of machine learning for biomarker discovery","volume":"394","author":"Ng","year":"2023","journal-title":"Cell Tissue Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"btad755","DOI":"10.1093\/bioinformatics\/btad755","article-title":"IntelliGenes: A novel machine learning pipeline for biomarker discovery and predictive analysis using multi-genomic profiles","volume":"39","author":"DeGroat","year":"2023","journal-title":"Bioinformatics"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Wasilewski, T., Kamysz, W., and G\u0119bicki, J. (2024). AI-Assisted Detection of Biomarkers by Sensors and Biosensors for Early Diagnosis and Monitoring. Biosensors, 14.","DOI":"10.3390\/bios14070356"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Bartusik-Aebisher, D., Justin Raj, D.R., and Aebisher, D. (2026). Artificial Intelligence in Medical Diagnostics: Foundations, Clinical Applications, and Future Directions. Appl. Sci., 16.","DOI":"10.3390\/app16020728"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Wen, S., Mo, S., Zhou, J., Lv, Y., Khazaie, K., and Yu, G. (2024). Editorial: Single-cell and spatial-omics in delineating immune-related diseases. Front. Cell Dev. Biol., 12.","DOI":"10.3389\/fcell.2024.1365242"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/s41576-023-00580-2","article-title":"Methods and applications for single-cell and spatial multi-omics","volume":"24","author":"Vandereyken","year":"2023","journal-title":"Nat. Rev. Genet."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jaci.2024.11.001","article-title":"Profiling immune cell tissue niches in the spatial-omics era","volume":"155","author":"Lee","year":"2025","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"103174","DOI":"10.1016\/j.copbio.2024.103174","article-title":"From single cell to spatial multi-omics: Unveiling molecular mechanisms in dynamic and heterogeneous systems","volume":"89","author":"Wu","year":"2024","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/25785826.2025.2567133","article-title":"A new era in atopic dermatitis treatment and evolving therapeutic strategies","volume":"49","author":"Honda","year":"2026","journal-title":"Immunol. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s40521-025-00390-3","article-title":"Innovations and Emerging Therapies in Atopic Dermatitis Part 1","volume":"12","author":"Okereke","year":"2025","journal-title":"Curr. Treat. Options Allergy"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Prados-Carmona, A., Navarro Trivi\u00f1o, F.J., Husein-ElAhmed, H., and Ruiz-Villaverde, R. (2025). Comparative real-world effectiveness and safety of biologics and JAK inhibitors in atopic dermatitis: Short- and medium-to-long-term analysis from a regional healthcare network in southern Spain. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1658843"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40629-025-00340-0","article-title":"Biologics in the treatment of atopic dermatitis: Approved active substances and monoclonal antibodies in advanced clinical trials","volume":"34","author":"Royeck","year":"2025","journal-title":"Allergo J. Int."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.jaip.2025.04.042","article-title":"Deciding Which Patients with Atopic Dermatitis to Prioritize for Biologics and Janus Kinase Inhibitors","volume":"13","author":"Kamata","year":"2025","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/all.13954","article-title":"Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis","volume":"75","author":"Bieber","year":"2020","journal-title":"Allergy"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"eaaw2938","DOI":"10.1126\/sciimmunol.aaw2938","article-title":"A key role for IL-13 signaling via the type 2 IL-4 receptor in experimental atopic dermatitis","volume":"5","author":"Bitton","year":"2020","journal-title":"Sci. Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/exd.13911","article-title":"Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches","volume":"28","author":"Moyle","year":"2019","journal-title":"Exp. Dermatol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s13555-025-01647-0","article-title":"Comparing the Efficacy and Safety of Nemolizumab Versus Anti-interleukin Monoclonal Antibody Therapies in Combination with Topical Treatments for Moderate-to-Severe Atopic Dermatitis Using Network Meta-analysis","volume":"16","author":"Pink","year":"2026","journal-title":"Dermatol. Ther."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Liang, J., Hu, F., Dan, M., Sang, Y., Abulikemu, K., Wang, Q., Hong, Y., and Kang, X. (2022). Safety and Efficacy of Nemolizumab for Atopic Dermatitis with Pruritus: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. Front. Immunol., 13, Correction in Front. Immunol. 2026, 17, 1773876.","DOI":"10.3389\/fimmu.2026.1773876"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bjd.20873","article-title":"Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: Results from two phase III, long-term studies","volume":"186","author":"Kabashima","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2576134","DOI":"10.1080\/09546634.2025.2576134","article-title":"Nemolizumab for the treatment of atopic dermatitis","volume":"36","author":"Rodrigues","year":"2025","journal-title":"J. Dermatol. Treat."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Mima, Y., Yamamoto, M., and Iozumi, K. (2025). Cutaneous Adverse Events Following Nemolizumab Administration: A Review. J. Clin. Med., 14.","DOI":"10.3390\/jcm14093026"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/1346-8138.17626","article-title":"Characteristics of suitable cases for treatment with nemolizumab based on clinical findings and cutaneous adverse events","volume":"52","author":"Sugiyama","year":"2025","journal-title":"J. Dermatol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"adv44310","DOI":"10.2340\/actadv.v105.44310","article-title":"The Absence of Recent Systemic Therapy can be a Significant Risk Factor for Nemolizumab-associated Cutaneous Adverse Events in Patients with Prurigo Nodularis: A Single-centre Retrospective Study","volume":"105","author":"Mima","year":"2025","journal-title":"Acta Derm. Venereol."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Livshits, G., and Kalinkovich, A. (2024). Resolution of Chronic Inflammation, Restoration of Epigenetic Disturbances and Correction of Dysbiosis as an Adjunctive Approach to the Treatment of Atopic Dermatitis. Cells, 13.","DOI":"10.3390\/cells13221899"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41423-023-00992-4","article-title":"The translational revolution in atopic dermatitis: The paradigm shift from pathogenesis to treatment","volume":"20","author":"Facheris","year":"2023","journal-title":"Cell Mol. Immunol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"eaba6500","DOI":"10.1126\/science.aba6500","article-title":"Developmental cell programs are co-opted in inflammatory skin disease","volume":"371","author":"Reynolds","year":"2021","journal-title":"Science"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.cell.2020.05.039","article-title":"Multimodal Analysis of Composition and Spatial Architecture in Human Squamous Cell Carcinoma","volume":"182","author":"Ji","year":"2020","journal-title":"Cell"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1097\/CM9.0000000000004020","article-title":"Artificial intelligence in atopic dermatitis: Current applications and future perspectives","volume":"139","author":"Chen","year":"2026","journal-title":"Chin. Med. J."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/14728214.2026.2667256","article-title":"Emerging microbiome-based therapies for atopic dermatitis: Clinical insights and future development","volume":"31","author":"Jones","year":"2026","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/s41565-025-02010-2","article-title":"Wearable biomolecular sensing nanotechnologies in chronic disease management","volume":"20","author":"Tu","year":"2025","journal-title":"Nat. Nanotechnol."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Wu, T., and Liu, G. (2025). Non-Invasive Wearables in Inflammation Monitoring: From Biomarkers to Biosensors. Biosensors, 15.","DOI":"10.3390\/bios15060351"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/bjd\/ljaf451","article-title":"From prebiotics to engineered microbes: Microbe-inspired treatments for atopic dermatitis","volume":"194","author":"Nevot","year":"2026","journal-title":"Br. J. Dermatol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/14\/6129\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T11:45:43Z","timestamp":1783683943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/14\/6129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":111,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["ijms27146129"],"URL":"https:\/\/doi.org\/10.3390\/ijms27146129","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]}}}